 |
인쇄하기
취소
|
KFDA approves first Alzheimer's skin patch
The Korea Food and Drug Administration has approved Exelon (rivastigmine) Patch, the first skin patch for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia, according to Novartis Korea.
Exelon (rivastigmine) Patch will be on the market in the latter half of next year.
Since 1997, Exelon (rivastigmine tartrate) has been widely used to treat mild to mode...
Exelon (rivastigmine) Patch will be on the market in the latter half of next year.
Since 1997, Exelon (rivastigmine tartrate) has been widely used to treat mild to mode...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.